MyFinsight
Home
Blog
About
Comprehensive loss
-$127,714K
(-26.56%↓ Y/Y)
Net loss
-$127,119K
(-26.19%↓ Y/Y)
Total other
comprehensive income (loss)
-$595K
(-238.07%↓ Y/Y)
Foreign currency
translation adjustment
$3K
License
$233K
Collaboration
$51K
Loss from operations
-$126,268K
(-18.27%↓ Y/Y)
Total other income
(expense), net
-$851K
(-114.11%↓ Y/Y)
Unrealized gain (loss) on
available-for-sale securities
-$598K
(-239.77%↓ Y/Y)
Total revenues
$284K
(278.67%↑ Y/Y)
Interest income
$8,490K
Other income
(expense), net
$156K
Total operating
expenses
$126,552K
(18.45%↑ Y/Y)
Interest expense
$8,307K
(1516.15%↑ Y/Y)
Change in fair value of
derivative liability
-$1,190K
Research and development
$71,577K
(-17.37%↓ Y/Y)
Selling, general and
administrative
$54,975K
Back
Back
Income Statement
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)
source: myfinsight.com